Quinazolines as apoptosis inducers and inhibitors: A review of patent literature

Samir Mehndiratta, Sameer Sapra, Gurpreet Singh, Manwinder Singh, Kunal Nepali

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Quinazoline scaffold has been successfully utilized for development of various inhibitors of tubulin, epidermal growth factor receptor (EGFR), polo like kinases (PLKs), Hedgehog-Gli signaling pathway and protein kinase B (PKB) /Akt pathway. Compounds based on quinazolines have shown efficacies in μM to nM range in various cancer cell lines and thus could be useful scaffolds for development of both apoptosis inducers as well as inhibitors. This compilation is based on various patents published till 2015 and divides the quinazolines in two main categories: Quinazolines as apoptosis inducers and as apoptosis inhibitors. These two main categories are further sub-categorized based on the use/pharmacological indications for these classes of patented compounds. This review will act as a tool for the researchers working on exploring the anticancer potential of quinazoline as a privileged heterocyclic. The promising anticancer profile of some of the quinazoline based compounds clearly highlights the clinical potential of this heterocycle.

Original languageEnglish
Pages (from-to)2-66
Number of pages65
JournalRecent Patents on Anti-Cancer Drug Discovery
Volume11
Issue number1
DOIs
Publication statusPublished - Feb 1 2016
Externally publishedYes

Fingerprint

Quinazolines
Patents
Apoptosis
Tubulin Modulators
Proto-Oncogene Proteins c-akt
Epidermal Growth Factor Receptor
Phosphotransferases
Research Personnel
Pharmacology
Cell Line
Neoplasms

Keywords

  • Apoptosis inducers
  • Apoptosis inhibitors
  • Cancer
  • Caspases
  • P53
  • Quinazolines
  • Tubulin

ASJC Scopus subject areas

  • Oncology
  • Drug Discovery
  • Cancer Research
  • Pharmacology (medical)

Cite this

Quinazolines as apoptosis inducers and inhibitors : A review of patent literature. / Mehndiratta, Samir; Sapra, Sameer; Singh, Gurpreet; Singh, Manwinder; Nepali, Kunal.

In: Recent Patents on Anti-Cancer Drug Discovery, Vol. 11, No. 1, 01.02.2016, p. 2-66.

Research output: Contribution to journalReview article

Mehndiratta, Samir ; Sapra, Sameer ; Singh, Gurpreet ; Singh, Manwinder ; Nepali, Kunal. / Quinazolines as apoptosis inducers and inhibitors : A review of patent literature. In: Recent Patents on Anti-Cancer Drug Discovery. 2016 ; Vol. 11, No. 1. pp. 2-66.
@article{415538cbb47f4e02944bfe229a99ff60,
title = "Quinazolines as apoptosis inducers and inhibitors: A review of patent literature",
abstract = "Quinazoline scaffold has been successfully utilized for development of various inhibitors of tubulin, epidermal growth factor receptor (EGFR), polo like kinases (PLKs), Hedgehog-Gli signaling pathway and protein kinase B (PKB) /Akt pathway. Compounds based on quinazolines have shown efficacies in μM to nM range in various cancer cell lines and thus could be useful scaffolds for development of both apoptosis inducers as well as inhibitors. This compilation is based on various patents published till 2015 and divides the quinazolines in two main categories: Quinazolines as apoptosis inducers and as apoptosis inhibitors. These two main categories are further sub-categorized based on the use/pharmacological indications for these classes of patented compounds. This review will act as a tool for the researchers working on exploring the anticancer potential of quinazoline as a privileged heterocyclic. The promising anticancer profile of some of the quinazoline based compounds clearly highlights the clinical potential of this heterocycle.",
keywords = "Apoptosis inducers, Apoptosis inhibitors, Cancer, Caspases, P53, Quinazolines, Tubulin",
author = "Samir Mehndiratta and Sameer Sapra and Gurpreet Singh and Manwinder Singh and Kunal Nepali",
year = "2016",
month = "2",
day = "1",
doi = "10.2174/1574892811666151218151506",
language = "English",
volume = "11",
pages = "2--66",
journal = "Recent Patents on Anti-Cancer Drug Discovery",
issn = "1574-8928",
publisher = "Bentham Science Publishers B.V.",
number = "1",

}

TY - JOUR

T1 - Quinazolines as apoptosis inducers and inhibitors

T2 - A review of patent literature

AU - Mehndiratta, Samir

AU - Sapra, Sameer

AU - Singh, Gurpreet

AU - Singh, Manwinder

AU - Nepali, Kunal

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Quinazoline scaffold has been successfully utilized for development of various inhibitors of tubulin, epidermal growth factor receptor (EGFR), polo like kinases (PLKs), Hedgehog-Gli signaling pathway and protein kinase B (PKB) /Akt pathway. Compounds based on quinazolines have shown efficacies in μM to nM range in various cancer cell lines and thus could be useful scaffolds for development of both apoptosis inducers as well as inhibitors. This compilation is based on various patents published till 2015 and divides the quinazolines in two main categories: Quinazolines as apoptosis inducers and as apoptosis inhibitors. These two main categories are further sub-categorized based on the use/pharmacological indications for these classes of patented compounds. This review will act as a tool for the researchers working on exploring the anticancer potential of quinazoline as a privileged heterocyclic. The promising anticancer profile of some of the quinazoline based compounds clearly highlights the clinical potential of this heterocycle.

AB - Quinazoline scaffold has been successfully utilized for development of various inhibitors of tubulin, epidermal growth factor receptor (EGFR), polo like kinases (PLKs), Hedgehog-Gli signaling pathway and protein kinase B (PKB) /Akt pathway. Compounds based on quinazolines have shown efficacies in μM to nM range in various cancer cell lines and thus could be useful scaffolds for development of both apoptosis inducers as well as inhibitors. This compilation is based on various patents published till 2015 and divides the quinazolines in two main categories: Quinazolines as apoptosis inducers and as apoptosis inhibitors. These two main categories are further sub-categorized based on the use/pharmacological indications for these classes of patented compounds. This review will act as a tool for the researchers working on exploring the anticancer potential of quinazoline as a privileged heterocyclic. The promising anticancer profile of some of the quinazoline based compounds clearly highlights the clinical potential of this heterocycle.

KW - Apoptosis inducers

KW - Apoptosis inhibitors

KW - Cancer

KW - Caspases

KW - P53

KW - Quinazolines

KW - Tubulin

UR - http://www.scopus.com/inward/record.url?scp=84958951726&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958951726&partnerID=8YFLogxK

U2 - 10.2174/1574892811666151218151506

DO - 10.2174/1574892811666151218151506

M3 - Review article

C2 - 26681186

AN - SCOPUS:84958951726

VL - 11

SP - 2

EP - 66

JO - Recent Patents on Anti-Cancer Drug Discovery

JF - Recent Patents on Anti-Cancer Drug Discovery

SN - 1574-8928

IS - 1

ER -